Medicamen Biotech Limited

As of June 30, 2026, Medicamen Biotech Limited carries a market capitalization of 3.39B, placing it among publicly traded companies globally. Its enterprise value stands at 3.39B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Medicamen Biotech Limited has 13.56M shares outstanding.

As of June 30, 2026, Medicamen Biotech Limited trades at a trailing price-to-earnings ratio of 35.25.

As of June 30, 2026, Medicamen Biotech Limited trades at an EV/EBITDA multiple of 17.58 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 28.05 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 3.39B versus a market cap of 3.39B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.19M in revenue per employee across its workforce of 390.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Medicamen Biotech Limited recorded 23.83M in income tax expense. That works out to an effective tax rate of 19.18, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 124.25M, leaving 102.77M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Medicamen Biotech Limited's stock has declined approximately 30.96% over the past 52 weeks. The 50-day moving average sits at 284.14, while the 200-day moving average is 281.34.

Over the twelve months ended June 30, 2026, Medicamen Biotech Limited generated 2.03B in revenue and converted that into 102.77M in net income, yielding earnings per share of 6.93. EBITDA reached 192.98M, while operating income came in at 120.94M.

Over the twelve months ended June 30, 2026, Medicamen Biotech Limited posted a gross margin of 50.56, reflecting its pricing power and cost economics. The operating margin of 5.97 and net profit margin of 5.07 provide insight into operational efficiency.